ArticleAbdominal radiology (New York)2026
Application of transrectal three-dimensional ultrasound for sub-staging of locally advanced rectal cancer at stage T3.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the value of transrectal three-dimensional ultrasound (3D-TRUS) in the T3 sub-staging of locally advanced rectal cancer.
methodsA retrospective analysis was conducted on patients with non-metastatic T3 stage rectal cancer who were diagnosed and treated at Fujian Cancer Hospital from December 2021 to December 2025. Preoperative T3 sub-staging data obtained via 3D-TRUS were compared with those obtained from the current standard magnetic resonance imaging (MRI) findings. The sensitivity, specificity, and Kappa statistic of the ultrasound method were evaluated.
resultsA total of 174 patients were included, achieving a lesion detection rate of 100%. 3D-TRUS demonstrated substantial agreement with magnetic resonance imaging (MRI) for determining T3 sub-staging (Kappa = 0.734, p < 0.001), with a specificity at 90.4%, a sensitivity at 83.3%, and an overall accuracy at 73.7%.
conclusion3D-TRUS demonstrates high accuracy in T3 sub-staging of locally advanced rectal cancer and offers a high-resolution, practical option for the clinical management of locally advanced rectal cancer.
Indexed as
Identifiers
42560491What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.